TB-500 is a synthetic thymosin beta-4 derivative with a development status of "preclinical". The Institute rates the strength of its published evidence as emerging. A synthetic version of a naturally occurring actin-binding peptide studied in models of tissue repair, cell migration, and cardiac injury.
This report covers the TB-500 samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Institute has independently tested 7 TB-500 samples from 6 companies. 100% met their label claims on purity and content. Measured purity ranged from 97.4% to 99.7%, averaging 98.3%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
